Morgan Stanley's client-screening faces deeper FINRA probe, WSJ reports

The U.S. Financial Industry Regulatory Authority (FINRA) is investigating Morgan Stanley over its client screening practices for money-laundering risks, encompassing wealth management (including E*Trade) and institutional trading operations from October 2021 through September 2024. This probe, which reportedly involved internal concerns about initial data accuracy, follows a $10 million FINRA fine levied against the bank in December 2018 for prior anti-money laundering compliance failures, highlighting ongoing regulatory scrutiny on the firm's controls.

Analysis

Morgan Stanley is facing a significant regulatory probe from the U.S. Financial Industry Regulatory Authority (FINRA) over its anti-money-laundering (AML) client screening practices. The investigation, which spans from October 2021 to September 2024, covers the firm's extensive wealth-management unit, including E*Trade, and its institutional securities division. This event is particularly noteworthy as it follows a previous $10 million FINRA fine in December 2018 for similar AML compliance failures, suggesting a persistent challenge in the firm's control environment. The situation is further complicated by reports of internal concerns that initial data provided to FINRA was incomplete or inaccurate, which could indicate deeper issues with internal controls and governance. While the company stated it has invested heavily in its AML programs, the investigation introduces material uncertainty and legal risk, as reflected by the moderately negative sentiment and themes of regulation and litigation.

Key Decisions for Investors

• Investors should closely monitor the FINRA investigation's progress, as any adverse findings could lead to substantial fines, reputational damage, and increased compliance costs.
• Given the history of a prior AML-related fine in 2018, this new probe warrants a critical assessment of Morgan Stanley's long-term governance and risk-management effectiveness.
• It may be prudent to factor in heightened legal and regulatory risk into valuation models for Morgan Stanley (MS) and consider adjusting exposure until there is greater clarity on the potential penalties and operational impact.